跳至主要内容
临床试验/IRCT20130313012810N30
IRCT20130313012810N30招募中Unknown

Bioequivalence study of Anagrelide 0.5 mg capsule manufactured by Modava Pharmaceutical Company

Modava Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • The weight range of participating candidates should be between 60-100 kg.
  • Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose.
  • Volunteers who have agreed to an informed consent form.
  • All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw.

排除标准

  • History of allergic or adverse reaction to Anagrelide or any similar product
  • Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg
  • Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s)

研究者

发起方
Modava Pharmaceutical Company

相似试验